EAN 2025 | Measuring treatment response in migraine: the role of PGIC in assessing treatment efficacy
Marina Romozzi, MD, PhD(c), Agostino Gemelli University Hospital Foundation IRCCS, Rome, Italy, comments on the limitations of current outcome measures for migraine treatment, suggesting that the patient global impression of change (PGIC) score may provide a more comprehensive assessment of treatment response. Dr Romozzi highlights the potential of PGIC as a proxy for evaluating treatment response to anti-CGRP monoclonal antibodies. This interview took place at the 11th Congress of the European Academy of Neurology (EAN 2025) in Helsinki, Finland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We conducted this study because right now the response to treatment is only defined with the reduction of 50% of monthly headache days. But still, patients that are considered responders may have significant residual burden and we think that this outcome measure may not reflect completely the complexity of migraine. So we wanted to evaluate instead a patient-reported outcome measure and in particular the patient global impression of change, which is a very rapid scale, in particular, it’s just a question with points going from zero to seven that really measure the satisfaction of the patient...
We conducted this study because right now the response to treatment is only defined with the reduction of 50% of monthly headache days. But still, patients that are considered responders may have significant residual burden and we think that this outcome measure may not reflect completely the complexity of migraine. So we wanted to evaluate instead a patient-reported outcome measure and in particular the patient global impression of change, which is a very rapid scale, in particular, it’s just a question with points going from zero to seven that really measure the satisfaction of the patient. So we included 179 patients and we showed with our results that the PGIC may really represent a proxy for evaluating treatment response to monoclonal antibodies against CGRP, even more than the reduction of monthly headache days. So we really suggest that in the future, both in real-world studies and clinical trials, the patient-reported outcome measure should really be included in the studies.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
